Image 1_Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.tif

Image 1_Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.tif

Introduction<p>The combination of anti-angiogenic agents, PD-1/L1 inhibitors, and hepatic arterial infusion chemotherapy (HAIC) has emerged as an important strategy for unresectable hepatocellular carcinoma (uHCC), yet comparative data on efficacy and safety between different anti-angiogenic a...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Lichang Huang (21412778) (author)
مؤلفون آخرون: Yujie Xu (1766401) (author), Na Liu (102929) (author), Hailong Chen (436622) (author), Zichao Wu (12735888) (author), Qijiong Li (14032517) (author), Minqiang Lu (10279616) (author), Wei Wei (21173) (author), Yaojun Zhang (389482) (author), Minshan Chen (151567) (author), Li Xu (108702) (author), Ming Shi (78991) (author), Zhicheng Lai (14032511) (author)
منشور في: 2025
الموضوعات:
Genetic Immunology
hepatocellular carcinoma
lenvatinib
bevacizumab
combination therapy
potential resectable
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة